Health Catalyst (NASDAQ:HCAT) Issues Earnings Results

Health Catalyst (NASDAQ:HCAT) released its earnings results on Monday. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.01, FiscalAI reports. The company had revenue of $76.32 million for the quarter, compared to analysts’ expectations of $75.05 million. Health Catalyst had a negative return on equity of 7.21% and a negative net margin of 31.67%. Health Catalyst updated its FY 2025 guidance to EPS and its Q4 2025 guidance to EPS.

Health Catalyst Price Performance

HCAT stock traded down $0.16 on Tuesday, reaching $2.69. The company had a trading volume of 964,154 shares, compared to its average volume of 694,093. The company’s fifty day moving average is $3.04 and its 200 day moving average is $3.51. The company has a market cap of $189.30 million, a P/E ratio of -1.78 and a beta of 1.64. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83. Health Catalyst has a 1 year low of $2.52 and a 1 year high of $9.24.

Institutional Trading of Health Catalyst

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Light Asset Management LLC lifted its holdings in Health Catalyst by 17.2% in the 2nd quarter. First Light Asset Management LLC now owns 12,230,181 shares of the company’s stock valued at $46,108,000 after purchasing an additional 1,793,374 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Health Catalyst by 2.9% in the third quarter. Vanguard Group Inc. now owns 4,295,691 shares of the company’s stock valued at $12,243,000 after buying an additional 119,117 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Health Catalyst by 11.4% during the second quarter. Geode Capital Management LLC now owns 1,662,455 shares of the company’s stock valued at $6,269,000 after buying an additional 169,580 shares during the period. Qube Research & Technologies Ltd boosted its position in Health Catalyst by 68.4% during the second quarter. Qube Research & Technologies Ltd now owns 282,281 shares of the company’s stock worth $1,064,000 after acquiring an additional 114,626 shares during the last quarter. Finally, WINTON GROUP Ltd grew its stake in Health Catalyst by 93.8% in the 2nd quarter. WINTON GROUP Ltd now owns 170,138 shares of the company’s stock worth $641,000 after acquiring an additional 82,336 shares during the period. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on HCAT shares. Piper Sandler cut Health Catalyst from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $8.00 to $4.00 in a research report on Wednesday, August 27th. Summit Redstone set a $5.00 price target on shares of Health Catalyst in a report on Friday, August 29th. Canaccord Genuity Group reduced their price objective on shares of Health Catalyst from $9.00 to $5.00 and set a “buy” rating for the company in a research note on Friday, August 29th. UBS Group restated an “outperform” rating on shares of Health Catalyst in a research report on Tuesday. Finally, BTIG Research reiterated a “neutral” rating on shares of Health Catalyst in a research report on Friday, September 5th. Five equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Health Catalyst currently has an average rating of “Hold” and an average price target of $4.36.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.